Cite

    Blauvelt, A. et al. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. British journal of dermatology. pp. 1348-1358. [Online].